Multifunctional nanomedicine prototypes acting as prophylactics and virus-assisted targeted drug delivery vehicle (NANOPROV)

作为预防剂和病毒辅助靶向药物输送载体的多功能纳米药物原型（NANOPROV）

• 批准号: MR/Y50337X/1
• 负责人: Kourosh Ebrahimi
• 金额: $ 22.48万
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY50337X%2F1
• 关键词: Multifunctional; nanomedicine; prototypes; acting; prophylactics

Unmet need. Viral infections are a global threat and the source of substantial social and economic burden. There is an increasing trend in the emergence and re-emergence of new viruses with high infectivity and mortality rates. Lessons learned from past pandemics, e.g. the global pandemic of SARS-CoV-2, demonstrate that a substantial amount of investment is needed to refine the science and technology to develop new early treatment antivirals. These antivirals should be based on a plug-in technology to be rapidly repurposed for treating the next fast-spreading virus and successfully managing pandemics. Approach and market. Among different technologies, pharmaceuticals based on nanoparticles show a high added value with an estimated compound annual growth rate of 22%. Protein-based nanopharmaceuticals are estimated to have a market size of $ 15 billion. NANOPROV will create novel protein-based prophylactic nanomedicines. The primary target group (> 8 million individuals in the UK alone) will be public servants and immunocompromised patients (e.g. cancer patients) and those requiring primary care. Innovative solution and background. NANOPROV will use a plug-in nanocage technology we have patented and built upon available data regarding antiviral binding proteins. It creates proof-of-concept efficacious antiviral prophylactic nanocages for early treatment. The plug-in technology can be quickly modified using genetic engineering and repurposed to create prophylactic nanocages against a new rapidly spreading virus. The project will generate the proof of concept product for developing inhalable formulations and preclinical tests. Our plug-in nanocage technology is based on the ubiquitous iron-storage protein of life ferritin. This naturally occurring nanocage protein is biocompatible, safe and stable and has shown an acceptable safety profile for making other therapeutics, such as vaccines.Team and environment. NANOPROV is a unique collaboration between experts in ferritin nanocages and those in antimicrobial therapeutics working at King's College London and the UK Health Security Agency (UKHSA). The Team has extensive experience developing antimicrobial products and collaborates with world-leading experts in inhalation drug delivery, formulation, and manufacturing and with biopharmaceutical companies. Expected impact. NANOPROV will refine the science and technology for developing early treatment protein-based nanopharmaceuticals. This unique cross-fertilisation of expertise and experience will create prototype antiviral nanomedicines and technological advances for rapid repurposing to counter a fast-spreading new virus. It will generate confidence in using our nanocage technology to develop other nanomedicines, including multivalent mosaic vaccines and multivalent anti-cancer immunotherapeutics.

未满足的需求。病毒感染是一种全球性威胁，也是巨大社会和经济负担的根源。具有高传染性和死亡率的新病毒的出现和重新出现呈增加趋势。从过去的流行病中吸取的教训，例如SARS-CoV-2 在全球大流行表明，需要大量投资来完善科学技术，以开发新的早期治疗抗病毒药物。这些抗病毒药物应基于插件技术，以便快速重新调整用途，以治疗下一个快速传播的病毒并成功控制流行病。方法和市场。在不同的技术中，基于纳米粒子的药物显示出较高的附加值，预计复合年增长率为22%。据估计，基于蛋白质的纳米药物的市场规模为150亿美元。 NANOPROV 将创造新型的基于蛋白质的预防性纳米药物。主要目标群体（仅在英国就有超过 800 万人）将是公务员和免疫功能低下的患者（例如癌症患者）以及需要初级护理的患者。创新的解决方案和背景。 NANOPROV 将使用我们已获得专利的插件式纳米笼技术，该技术基于有关抗病毒结合蛋白的可用数据。它创建了用于早期治疗的有效抗病毒预防性纳米笼的概念验证。该插件技术可以利用基因工程进行快速修改，并重新调整用途，以创建针对新的快速传播病毒的预防性纳米笼。该项目将为开发吸入制剂和临床前测试提供概念验证产品。我们的插入式纳米笼技术基于普遍存在的生命铁蛋白的储铁蛋白。这种天然存在的纳米笼蛋白具有生物相容性、安全性和稳定性，并且对于制造疫苗等其他治疗方法显示出可接受的安全性。团队和环境。 NANOPROV 是铁蛋白纳米笼专家与伦敦国王学院和英国卫生安全局 (UKHSA) 抗菌治疗专家之间的独特合作。该团队在开发抗菌产品方面拥有丰富的经验，并与吸入药物输送、配方和制造领域的世界领先专家以及生物制药公司合作。预期影响。 NANOPROV 将完善开发早期治疗蛋白质纳米药物的科学和技术。这种独特的专业知识和经验的交叉融合将创造抗病毒纳米药物原型和技术进步，以便快速重新利用以对抗快速传播的新病毒。它将增强人们使用我们的纳米笼技术开发其他纳米药物的信心，包括多价嵌合疫苗和多价抗癌免疫疗法。